Adagene Inc-adr (ADAG)

$2.35

-0.4

(-14.55%)▲

Market is closed - opens 7 PM, 26 Apr 2024

Insights on Adagene Inc-adr

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 407.87K → 833.33K (in $), with an average increase of 51.1% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 4 quarters, -2.05M → -15.15M (in $), with an average decrease of 95.0% per quarter

Performance

  • $2.32
    $2.77
    $2.35
    downward going graph

    1.28%

    Downside

    Day's Volatility :16.27%

    Upside

    15.19%

    downward going graph
  • $1.10
    $4.38
    $2.35
    downward going graph

    53.19%

    Downside

    52 Weeks Volatility :74.89%

    Upside

    46.35%

    downward going graph

Returns

PeriodAdagene Inc-adrSector (Health Care)Index (Russel 2000)
3 Months
-30.38%
1.1%
0.0%
6 Months
105.22%
12.5%
0.0%
1 Year
102.95%
6.9%
2.2%
3 Years
-80.61%
14.3%
-23.0%

Highlights

Market Capitalization
117.0M
Book Value
$1.6
Earnings Per Share (EPS)
-0.44
Wall Street Target Price
12.0
Profit Margin
-104.61%
Operating Margin TTM
-2288.81%
Return On Assets TTM
-11.06%
Return On Equity TTM
-24.66%
Revenue TTM
18.1M
Revenue Per Share TTM
0.41
Quarterly Revenue Growth YOY
-84.8%
Gross Profit TTM
10.2M
EBITDA
-22.7M
Diluted Eps TTM
-0.44
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.66
EPS Estimate Next Year
-0.9
EPS Estimate Current Quarter
-0.42
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    88%Buy
    11%Hold
    0
    0%Sell
Based on 9 Wall street analysts offering stock ratings for Adagene Inc-adr(by analysts ranked 0 to 5 stars)
Based on 9 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
8
8
10
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 410.64%

Current $2.35
Target $12.00

Technicals Summary

Sell

Neutral

Buy

Adagene Inc-adr is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Adagene Inc-adr
Adagene Inc-adr
7.42%
105.22%
102.95%
-80.61%
-80.61%
Moderna, Inc.
Moderna, Inc.
1.34%
41.81%
-16.73%
-38.71%
314.51%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-5.68%
13.74%
14.81%
80.88%
159.02%
Novo Nordisk A/s
Novo Nordisk A/s
-2.24%
29.49%
49.67%
240.51%
421.0%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-3.67%
10.39%
20.74%
84.71%
129.52%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Adagene Inc-adr
Adagene Inc-adr
NA
NA
NA
-1.66
-0.25
-0.11
NA
1.6
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-6.77
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.13
26.13
1.46
45.02
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
48.36
48.36
2.4
3.34
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
29.17
29.17
0.53
16.75
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Adagene Inc-adr
Adagene Inc-adr
Buy
$117.0M
-80.61%
NA
-104.61%
Moderna, Inc.
Moderna, Inc.
Buy
$41.3B
314.51%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$99.6B
159.02%
26.13
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$573.9B
421.0%
48.36
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$104.7B
129.52%
29.17
36.68%

Institutional Holdings

  • Wuxi AppTec Co Ltd

    9.58%

  • SC China Holding Ltd

    3.05%

  • Artal Group S A

    2.27%

  • General Atlantic Llc

    0.60%

  • Morgan Stanley - Brokerage Accounts

    0.33%

  • FMR Inc

    0.28%

Corporate Announcements

  • Adagene Inc-adr Earnings

    Adagene Inc-adr’s price-to-earnings ratio stands at None

    Read More

Company Information

adagene was co-founded by two serial entrepreneurs to power antibody discovery. its aim is to become the leading player in antibody discovery and engineering. it has developed a proprietary dynamic precision library (dpl) and is showcasing the power of the library with a unique pipeline of innovative antibody therapeutics that is advancing into clinical trials. adagene previously has raised three series of financing with over $86 million. investors include f-prime capital (formerly fidelity biosciences), eight roads ventures china (formerly fidelity growth partners asia), 6 dimensions capital, gp healthcare capital, sequoia china, and new world tmt. for more information, please visit www.adagene.com.

Organization
Adagene Inc-adr
Employees
174
CEO
Dr. Peter P. Luo Ph.D.
Industry
Healthcare

Discover More

FAQs